The drug eluting stent market size has grown strongly in recent years. It will grow from $7.05 billion in 2023 to $7.63 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The historical growth can be attributed to the necessity for enhanced treatment options, clinical evidence, regulatory approvals, healthcare economics, and guidelines and recommendations.
The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $10.52 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth in the forecast period can be attributed to factors such as an aging population and the burden of chronic diseases, expanded indications, healthcare reimbursement policies, global market expansion, and the emphasis on patient-centered care. Significant trends expected in the forecast period encompass personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.
The increasing burden of coronary heart disease is projected to drive the expansion of the drug-eluting stent market in the future. Coronary heart disease (CHD) occurs when the coronary arteries become narrowed or blocked due to plaque accumulation, potentially leading to severe complications such as heart attacks or chest pain. Sedentary lifestyles, poor dietary habits, aging populations, and heightened awareness contribute to the rising prevalence of coronary heart disease. Drug-eluting stents (DES) play a crucial role in managing coronary heart disease by effectively widening narrowed or blocked coronary arteries and releasing medication to prevent re-narrowing (restenosis) of the artery. For example, according to the Centers for Disease Control and Prevention, the percentage of adults aged 18 and over with coronary heart disease increased from 4.6% in 2020 to 4.9% in 2022. This upward trend in coronary heart disease burden is expected to fuel the growth of the drug-eluting stent market.
Companies operating in the drug-eluting stent market are directing their efforts toward developing innovative delivery systems, such as the dual-layer balloon, to enhance patient outcomes and advance interventional cardiology. A dual-layer balloon within a drug-eluting stent system improves precision in drug delivery and stent deployment by offering better control and uniform drug application to the arterial wall. For instance, in August 2022, Medtronic Plc introduced Onyx Frontier, the latest generation of drug-eluting coronary stent systems designed to enhance delivery systems, building upon the acute performance and clinical data from the previous Resolute Onyx DES generation. The Onyx Frontier DES utilizes the same high-quality stent platform as Resolute Onyx and features a wide size range to treat patients with diameters ranging from 2.0mm to 5.0mm. Notable design enhancements include a groundbreaking dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility, resulting in a 16% increase in deliverability compared to the previous Resolute Onyx DES generation, while maintaining radial strength.
In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.
Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.
North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.
The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.
The drug eluting stent market research report is one of a series of new reports that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $10.52 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth in the forecast period can be attributed to factors such as an aging population and the burden of chronic diseases, expanded indications, healthcare reimbursement policies, global market expansion, and the emphasis on patient-centered care. Significant trends expected in the forecast period encompass personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.
The increasing burden of coronary heart disease is projected to drive the expansion of the drug-eluting stent market in the future. Coronary heart disease (CHD) occurs when the coronary arteries become narrowed or blocked due to plaque accumulation, potentially leading to severe complications such as heart attacks or chest pain. Sedentary lifestyles, poor dietary habits, aging populations, and heightened awareness contribute to the rising prevalence of coronary heart disease. Drug-eluting stents (DES) play a crucial role in managing coronary heart disease by effectively widening narrowed or blocked coronary arteries and releasing medication to prevent re-narrowing (restenosis) of the artery. For example, according to the Centers for Disease Control and Prevention, the percentage of adults aged 18 and over with coronary heart disease increased from 4.6% in 2020 to 4.9% in 2022. This upward trend in coronary heart disease burden is expected to fuel the growth of the drug-eluting stent market.
Companies operating in the drug-eluting stent market are directing their efforts toward developing innovative delivery systems, such as the dual-layer balloon, to enhance patient outcomes and advance interventional cardiology. A dual-layer balloon within a drug-eluting stent system improves precision in drug delivery and stent deployment by offering better control and uniform drug application to the arterial wall. For instance, in August 2022, Medtronic Plc introduced Onyx Frontier, the latest generation of drug-eluting coronary stent systems designed to enhance delivery systems, building upon the acute performance and clinical data from the previous Resolute Onyx DES generation. The Onyx Frontier DES utilizes the same high-quality stent platform as Resolute Onyx and features a wide size range to treat patients with diameters ranging from 2.0mm to 5.0mm. Notable design enhancements include a groundbreaking dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility, resulting in a 16% increase in deliverability compared to the previous Resolute Onyx DES generation, while maintaining radial strength.
In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.
Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.
North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.
The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.
The drug eluting stent market research report is one of a series of new reports that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Drug Eluting Stent Market Characteristics3. Drug Eluting Stent Market Trends and Strategies32. Global Drug Eluting Stent Market Competitive Benchmarking33. Global Drug Eluting Stent Market Competitive Dashboard34. Key Mergers and Acquisitions in the Drug Eluting Stent Market
4. Drug Eluting Stent Market - Macro Economic Scenario
5. Global Drug Eluting Stent Market Size and Growth
6. Drug Eluting Stent Market Segmentation
7. Drug Eluting Stent Market Regional and Country Analysis
8. Asia-Pacific Drug Eluting Stent Market
9. China Drug Eluting Stent Market
10. India Drug Eluting Stent Market
11. Japan Drug Eluting Stent Market
12. Australia Drug Eluting Stent Market
13. Indonesia Drug Eluting Stent Market
14. South Korea Drug Eluting Stent Market
15. Western Europe Drug Eluting Stent Market
16. UK Drug Eluting Stent Market
17. Germany Drug Eluting Stent Market
18. France Drug Eluting Stent Market
19. Italy Drug Eluting Stent Market
20. Spain Drug Eluting Stent Market
21. Eastern Europe Drug Eluting Stent Market
22. Russia Drug Eluting Stent Market
23. North America Drug Eluting Stent Market
24. USA Drug Eluting Stent Market
25. Canada Drug Eluting Stent Market
26. South America Drug Eluting Stent Market
27. Brazil Drug Eluting Stent Market
28. Middle East Drug Eluting Stent Market
29. Africa Drug Eluting Stent Market
30. Drug Eluting Stent Market Competitive Landscape and Company Profiles
31. Drug Eluting Stent Market Other Major and Innovative Companies
35. Drug Eluting Stent Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Drug Eluting Stent Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on drug eluting stent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug eluting stent? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drug eluting stent market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Polymer-Based; Polymer-Free2) By Drug: Sirolimus; Paclitaxel; Zotarolimus; Everolimus; Biolimus; Other Drugs
3) By Scaffold: Cobalt-Chromium; Platinum-Chromium; Nitinol; Biodegradable; Other Scaffolds
4) By Application: Coronary Diseases; Peripheral Vascular Diseases
5) By End-User: Hospitals; Specialty Clinics
Key Companies Mentioned: Johnson & Johnson Services Inc.; Abbott; Medtronic plc; Boston Scientific Corporation; Terumo Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson & Johnson Services Inc.
- Abbott
- Medtronic plc
- Boston Scientific Corporation
- Terumo Corporation
- InspireMD Inc.
- B. Braun Melsungen AG
- Cook Group Incorporated
- Lepu Medical Technology (Beijing) Co. Ltd.
- Biotronik
- Meril Life Sciences Pvt. Ltd.
- MicroPort Scientific Corporation
- Biosensors International Group Ltd.
- OrbusNeich Medical Company Limited
- Alvimedica Medical Technologies
- Hexacath
- Elixir Medical Corporation
- Translumina GmbH
- Cardionovum GmbH
- QualiMed Innovative Medizinprodukte GmbH
- InSitu Technologies Inc.
- Acrostak AG
- SINOMED Innovation Inc.
- Svelte Medical Systems Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 7.63 Billion |
Forecasted Market Value ( USD | $ 10.52 Billion |
Compound Annual Growth Rate | 8.4% |
Regions Covered | Global |